Use access key #2 to skip to page content.
$10.25 0.62 (6.44%)
9/5/2008 3:30 PM

Sucampo Pharmaceuticals, Inc. (SCMP)

CAPS Rating:
**

An emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SCMP

Add Stock to Watchlist

What the Community Thinks

Total Members

22 Outperforms
15 Underperforms
 

All-Stars

6 Outperforms
3 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on SCMP are also bullish on:

Members bearish on SCMP are also bearish on:

Ticker Tags

Micro Cap (4824), IPO in 2007 (239), Pharmaceutical (31)
Suggest a tag

Sucampo Pharmaceuticals, Inc. At A Glance

Current Price: $10.25
Last Trade Time: 9/5/2008 3:30 PM
Open: $9.94
Previous Close: $9.63
Daily Range: $9.75 - $10.26
52-Week Range: $7.52 - $19.75
Volume: 53,832
Market Cap: $150.30M
P/E Ratio: 14.37
Compare Our Special Broker Offers!

Stock Trends

SCMP VS S&P 500 (SPY)

SCMP 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for SCMP

More Headlines...

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 2 of 2  

Show Pitch Replies

Recs

0

 (SCMP)

Avatar 39100 (< 20) Submitted: 7/11/08 3:44 PM : Outperform Start Price: $10.75 SCMP Score: -4.63

Pharmeceuticals dude.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SCMP)

Avatar drugncover (31.75) Submitted: 10/04/07 10:28 PM : Underperform Start Price: $12.79 SCMP Score: 1.13

Talk about inside dealing... reading the prospectus of this company is like wading through a swamp. They hold certain rights to all their compounds in a separate company, that the CEO of this company and his wife own, and have cut deals on the molecule that screw SCMP out of upside. They have sold drugs between five different subsidiaries from Asia, to North and South America, to Germany for what looks like only tax advantage, without any regard for what is best for the company. On top of this, they retain preferred shares that essentially prevent any shareholder from having any rights in SCMP. Add on the fact that they gave themselves fat bonuses based on EXPIRED options they used to hold in the company prior to IPO, and that the bulk of the IPO shares were not new shares, but them selling shares they held in other subsidiaries they still control... the CEO and his wife (who used to be chairman of the board) are clearly just using this company as a personal bank.
On the market side, they got a huge boost to revenue because of the Zelnorm withdrawal, which helped this IPO go up after issue... but Zelnorm is back, and there are IBS drugs coming up the pipeline left and right. Their revenue will likely decline next quarter (if the monthly script data showing Zelnorm coming back into the market hold true) and their pipeline is only mediocre.
Who knows in the end, but I can't help but feel any company so clearly structured to enrich the couple who runs it can't help but take away shareholder value in the end... hence my underperform.

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 2 of 2  

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCowenandCo 79.31 09/12/07 Outperform NS $13.57-24.47%-15.74%-8.73
TrackLeerinkSwan 99.09 09/12/07 Outperform NS $13.50-24.07%-15.93%-8.14

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners